Novel Liposomal Rolipram Formulation for Clinical Application to Reduce Emesis

INTRODUCTION: The phosphodiesterase 4 (PDE4) inhibitor, rolipram, has beneficial effects on tissue inflammation, injury and fibrosis, including in the liver. Since rolipram elicits significant CNS side-effects in humans (ie, nausea and emesis), our group developed a fusogenic lipid vesicle (FLV) dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Gobejishvili, Leila, Rodriguez, Walter E, Bauer, Philip, Wang, Yali, Soni, Chirag, Lydic, Todd, Barve, Shirish, McClain, Craig, Maldonado, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078351/
https://www.ncbi.nlm.nih.gov/pubmed/35535222
http://dx.doi.org/10.2147/DDDT.S355796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078351/
https://www.ncbi.nlm.nih.gov/pubmed/35535222
http://dx.doi.org/10.2147/DDDT.S355796

Ejemplares similares